TVRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Tvardi Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.97−0.04 (-3.96%)
Close on Oct 19, 2026
- Market cap
- $9.10M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Tvardi Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | Q2 23 | Q1 23 | Q4 22 | Q3 22 | Q2 22 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other revenue (non-cash) [Member] | $1.32M | $1.46M | $1.26M | $991.00K | $623.00K | $699.00K | $0 | $0 | $0 | – | – | – | 51.5% | +112.4% |
| Other revenue | $1.32M | $1.46M | $1.26M | $991.00K | $623.00K | – | – | – | – | – | – | – | 51.5% | +112.4% |
| Collaborative revenue | $1.20M | $0 | $1.30M | $0 | $788.00K | $2.31M | $2.47M | $5.41M | $2.75M | $1.13M | $7.44M | $8.00M | 46.6% | +52.0% |
| Clinical compound revenue | $48.00K | $0 | $0 | $0 | $84.00K | $0 | $66.00K | $0 | $99.00K | – | – | – | 1.9% | -42.9% |
| License and milestone fees [Member] | – | – | – | – | – | $0 | $910.00K | – | – | $0 | $0 | $15.00M | – | – |
| Commercial supply revenue | – | $0 | $0 | $0 | $640.00K | $0 | $1.25M | $1.40M | $3.19M | $2.06M | $3.37M | $0 | – | – |
| Royalty revenue | – | – | – | – | – | $0 | $167.00K | $123.00K | $125.00K | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Tvardi Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.